Standard
Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial. / Burn, John; Gerdes, Anne-Marie; Macrae, Finlay; Mecklin, Jukka-Pekka; Moeslein, Gabriela; Olschwang, Sylviane; Eccles, Diane; Evans, D Gareth; Maher, Eamonn R; Bertario, Lucio; Bisgaard, Søs Marie Luise; Dunlop, Malcolm G; Ho, Judy W C; Hodgson, Shirley V; Lindblom, Annika; Lubinski, Jan; Morrison, Patrick J; Murday, Victoria; Ramesar, Raj; Side, Lucy; Scott, Rodney J; Thomas, Huw J W; Vasen, Hans F; Barker, Gail; Crawford, Gillian; Elliott, Faye; Movahedi, Mohammad; Pylvanainen, Kirsi; Wijnen, Juul T; Fodde, Riccardo; Lynch, Henry T; Mathers, John C; Bishop, D Timothy; CAPP2 Investigators.
I:
Lancet, Bind 378, Nr. 9809, 2011, s. 2081-7.
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Harvard
Burn, J
, Gerdes, A-M, Macrae, F, Mecklin, J-P, Moeslein, G, Olschwang, S, Eccles, D, Evans, DG, Maher, ER, Bertario, L, Bisgaard, SML, Dunlop, MG, Ho, JWC, Hodgson, SV, Lindblom, A, Lubinski, J, Morrison, PJ, Murday, V, Ramesar, R, Side, L, Scott, RJ, Thomas, HJW, Vasen, HF, Barker, G, Crawford, G, Elliott, F, Movahedi, M, Pylvanainen, K, Wijnen, JT, Fodde, R, Lynch, HT, Mathers, JC, Bishop, DT & CAPP2 Investigators 2011, '
Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial',
Lancet, bind 378, nr. 9809, s. 2081-7.
https://doi.org/10.1016/S0140-6736(11)61049-0APA
Burn, J.
, Gerdes, A-M., Macrae, F., Mecklin, J-P., Moeslein, G., Olschwang, S., Eccles, D., Evans, D. G., Maher, E. R., Bertario, L., Bisgaard, S. M. L., Dunlop, M. G., Ho, J. W. C., Hodgson, S. V., Lindblom, A., Lubinski, J., Morrison, P. J., Murday, V., Ramesar, R., ... CAPP2 Investigators (2011).
Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial.
Lancet,
378(9809), 2081-7.
https://doi.org/10.1016/S0140-6736(11)61049-0Vancouver
Burn J
, Gerdes A-M, Macrae F, Mecklin J-P, Moeslein G, Olschwang S o.a.
Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial.
Lancet. 2011;378(9809):2081-7.
https://doi.org/10.1016/S0140-6736(11)61049-0Author
Burn, John ; Gerdes, Anne-Marie ; Macrae, Finlay ; Mecklin, Jukka-Pekka ; Moeslein, Gabriela ; Olschwang, Sylviane ; Eccles, Diane ; Evans, D Gareth ; Maher, Eamonn R ; Bertario, Lucio ; Bisgaard, Søs Marie Luise ; Dunlop, Malcolm G ; Ho, Judy W C ; Hodgson, Shirley V ; Lindblom, Annika ; Lubinski, Jan ; Morrison, Patrick J ; Murday, Victoria ; Ramesar, Raj ; Side, Lucy ; Scott, Rodney J ; Thomas, Huw J W ; Vasen, Hans F ; Barker, Gail ; Crawford, Gillian ; Elliott, Faye ; Movahedi, Mohammad ; Pylvanainen, Kirsi ; Wijnen, Juul T ; Fodde, Riccardo ; Lynch, Henry T ; Mathers, John C ; Bishop, D Timothy ; CAPP2 Investigators. / Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial. I: Lancet. 2011 ; Bind 378, Nr. 9809. s. 2081-7.
Bibtex
@article{a8318c34b54c4f4798409e5fe505ca4d,
title = "Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial",
abstract = "Observational studies report reduced colorectal cancer in regular aspirin consumers. Randomised controlled trials have shown reduced risk of adenomas but none have employed prevention of colorectal cancer as a primary endpoint. The CAPP2 trial aimed to investigate the antineoplastic effects of aspirin and a resistant starch in carriers of Lynch syndrome, the major form of hereditary colorectal cancer; we now report long-term follow-up of participants randomly assigned to aspirin or placebo.",
keywords = "Adenoma, Anti-Inflammatory Agents, Non-Steroidal, Aspirin, Chemoprevention, Colorectal Neoplasms, Hereditary Nonpolyposis, Dietary Carbohydrates, Double-Blind Method, Heterozygote, Humans, Starch",
author = "John Burn and Anne-Marie Gerdes and Finlay Macrae and Jukka-Pekka Mecklin and Gabriela Moeslein and Sylviane Olschwang and Diane Eccles and Evans, {D Gareth} and Maher, {Eamonn R} and Lucio Bertario and Bisgaard, {S{\o}s Marie Luise} and Dunlop, {Malcolm G} and Ho, {Judy W C} and Hodgson, {Shirley V} and Annika Lindblom and Jan Lubinski and Morrison, {Patrick J} and Victoria Murday and Raj Ramesar and Lucy Side and Scott, {Rodney J} and Thomas, {Huw J W} and Vasen, {Hans F} and Gail Barker and Gillian Crawford and Faye Elliott and Mohammad Movahedi and Kirsi Pylvanainen and Wijnen, {Juul T} and Riccardo Fodde and Lynch, {Henry T} and Mathers, {John C} and Bishop, {D Timothy} and {CAPP2 Investigators}",
note = "Copyright {\textcopyright} 2011 Elsevier Ltd. All rights reserved.",
year = "2011",
doi = "10.1016/S0140-6736(11)61049-0",
language = "English",
volume = "378",
pages = "2081--7",
journal = "The Lancet",
issn = "0140-6736",
publisher = "TheLancet Publishing Group",
number = "9809",
}
RIS
TY - JOUR
T1 - Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial
AU - Burn, John
AU - Gerdes, Anne-Marie
AU - Macrae, Finlay
AU - Mecklin, Jukka-Pekka
AU - Moeslein, Gabriela
AU - Olschwang, Sylviane
AU - Eccles, Diane
AU - Evans, D Gareth
AU - Maher, Eamonn R
AU - Bertario, Lucio
AU - Bisgaard, Søs Marie Luise
AU - Dunlop, Malcolm G
AU - Ho, Judy W C
AU - Hodgson, Shirley V
AU - Lindblom, Annika
AU - Lubinski, Jan
AU - Morrison, Patrick J
AU - Murday, Victoria
AU - Ramesar, Raj
AU - Side, Lucy
AU - Scott, Rodney J
AU - Thomas, Huw J W
AU - Vasen, Hans F
AU - Barker, Gail
AU - Crawford, Gillian
AU - Elliott, Faye
AU - Movahedi, Mohammad
AU - Pylvanainen, Kirsi
AU - Wijnen, Juul T
AU - Fodde, Riccardo
AU - Lynch, Henry T
AU - Mathers, John C
AU - Bishop, D Timothy
AU - CAPP2 Investigators
N1 - Copyright © 2011 Elsevier Ltd. All rights reserved.
PY - 2011
Y1 - 2011
N2 - Observational studies report reduced colorectal cancer in regular aspirin consumers. Randomised controlled trials have shown reduced risk of adenomas but none have employed prevention of colorectal cancer as a primary endpoint. The CAPP2 trial aimed to investigate the antineoplastic effects of aspirin and a resistant starch in carriers of Lynch syndrome, the major form of hereditary colorectal cancer; we now report long-term follow-up of participants randomly assigned to aspirin or placebo.
AB - Observational studies report reduced colorectal cancer in regular aspirin consumers. Randomised controlled trials have shown reduced risk of adenomas but none have employed prevention of colorectal cancer as a primary endpoint. The CAPP2 trial aimed to investigate the antineoplastic effects of aspirin and a resistant starch in carriers of Lynch syndrome, the major form of hereditary colorectal cancer; we now report long-term follow-up of participants randomly assigned to aspirin or placebo.
KW - Adenoma
KW - Anti-Inflammatory Agents, Non-Steroidal
KW - Aspirin
KW - Chemoprevention
KW - Colorectal Neoplasms, Hereditary Nonpolyposis
KW - Dietary Carbohydrates
KW - Double-Blind Method
KW - Heterozygote
KW - Humans
KW - Starch
U2 - 10.1016/S0140-6736(11)61049-0
DO - 10.1016/S0140-6736(11)61049-0
M3 - Journal article
C2 - 22036019
VL - 378
SP - 2081
EP - 2087
JO - The Lancet
JF - The Lancet
SN - 0140-6736
IS - 9809
ER -
